Cibc World Market Inc. grew its stake in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 6.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 52,168 shares of the company’s stock after acquiring an additional 3,244 shares during the period. Cibc World Market Inc.’s holdings in AstraZeneca were worth $8,498,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of AZN. Professional Advisory Services Inc. bought a new stake in AstraZeneca in the second quarter worth $30,241,000. Wealthcare Advisory Partners LLC purchased a new position in shares of AstraZeneca during the second quarter worth approximately $2,296,000. Andra AP fonden raised its position in AstraZeneca by 122.9% during the 2nd quarter. Andra AP fonden now owns 526,714 shares of the company’s stock valued at $99,876,000 after purchasing an additional 290,412 shares in the last quarter. International Assets Investment Management LLC lifted its stake in AstraZeneca by 1,564.8% in the third quarter. International Assets Investment Management LLC now owns 28,785 shares of the company’s stock worth $4,648,000 after acquiring an additional 27,056 shares during the period. Finally, Westport Asset Management Inc. purchased a new stake in shares of AstraZeneca in the 2nd quarter worth approximately $1,422,000. 20.35% of the stock is owned by institutional investors and hedge funds.
AstraZeneca Trading Down 0.7%
Shares of NYSE AZN opened at $174.20 on Friday. The stock has a market capitalization of $270.17 billion, a PE ratio of 24.64, a PEG ratio of 1.43 and a beta of 0.24. The company has a current ratio of 1.01, a quick ratio of 0.79 and a debt-to-equity ratio of 0.51. The stock has a fifty day simple moving average of $170.72 and a 200-day simple moving average of $180.02. AstraZeneca Plc has a twelve month low of $153.41 and a twelve month high of $212.71.
AstraZeneca (NYSE:AZN – Get Free Report) last issued its quarterly earnings results on Saturday, October 31st. The company reported $2.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.60 by $0.19. The business had revenue of $16.21 billion for the quarter, compared to analysts’ expectations of $16 billion. AstraZeneca had a net margin of 17.68% and a return on equity of 31.85%. The business’s quarterly revenue was up 6.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.38 earnings per share. On average, equities analysts forecast that AstraZeneca Plc will post 10.22 earnings per share for the current year.
Analysts Set New Price Targets
AZN has been the topic of a number of recent analyst reports. Wall Street Zen raised AstraZeneca from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. CICC Research assumed coverage on shares of AstraZeneca in a research note on Sunday, August 23rd. They set an “outperform” rating and a $198.00 price objective for the company. Royal Bank Of Canada began coverage on AstraZeneca in a research note on Tuesday, September 8th. They issued an “outperform” rating on the stock. Citigroup restated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, October 6th. Finally, Zacks Research raised AstraZeneca from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 13th. Sixteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, AstraZeneca has an average rating of “Moderate Buy” and an average price target of $206.67.
View Our Latest Stock Report on AZN
AstraZeneca Profile
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
Further Reading
- Five stocks we like better than AstraZeneca
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
